顺铂用于非小细胞肺癌化疗的药效学研究  

Pharmacodynamics of Cisplatin in Patients with Nonsmall-cell Lung Cancer

作　　者：安鸿志[1] 于卫江[1] 李杰[2] 张斌[1] 田锋奇[1] 

机构地区：[1]河南省肿瘤医院药剂科,郑州市450008 [2]河南省肿瘤医院肿瘤研究所,郑州市450008

出　　处：《中国药房》2008年第35期2767-2769,共3页China Pharmacy

基　　金：河南省省属科研院所研究专项基金项目(0441130404)

摘　　要：目的:寻找顺铂药动学参数与疗效和毒性的关系。方法:16例非小细胞肺癌化疗患者使用顺铂不同剂量联合长春瑞滨方案治疗,动态采集患者0～96h血样本,高效液相色谱法测定给药后顺铂的血药浓度。按世界卫生组织制定的疗效和毒副作用分级标准评价疗效和药物不良反应,采用统计学方法和药动学软件进行分析。结果:在疗效方面,CR+PR组和SD+PD组的AUC值有显著性差异(P<0.05),其余两组的药动学参数无显著性差异(P>0.05);在恶心呕吐方面,0～Ⅱ度组和Ⅲ～Ⅳ度组的药动学参数无显著性差异(P>0.05);在骨髓抑制方面,WBC减少组和WBC未减少组的Vc值有显著性差异(P<0.05),其余两组的药动学参数无显著性差异(P>0.05)。结论:AUC值、Vc值分别与疗效、白细胞减少症存在一定相关性。OBJECTIVE： To study the correlation between the pharmacokinetic parameters of cisplatin and its efficacy and toxicity in patients with nonsmall- cell lung cancer （NSCLC） . METHODS： 16 patients with NSCLC were treated with cisplatin （DDP） in combination with vinorelbine （NVB） by intravenous drop infusion in two different schemes. Patient＇ s blood samples from 0 to 96h were taken dynamically. The plasma concentration of cisplatin was determined by HPLC. The curative effect and the grading of adverse effects were evaluated in accordance with the standard recommended by WHO. The Pharmacokinetics software was adopted for and statistical analysis of the data. RESULTS： In terms of curative effect, the pharmacokinetic parameters had no significant difference （P 〉0.05） between CR ＋ PR and SD ＋ PD group except AUC （P 〈 0.05）. The parameters of pharmacokinetics had no significant differenee（P 〉0.05） in nausea and vomiting between 0- Ⅱ degree group and Ⅲ-Ⅳ degree group. The pharmacokinetic parameters had no significant difference （P 〉 0.05） between leukopenia group and none - leuk- openia group except Vc value（P 〈 0.05）. CONCLUSION： A correlation was noted between curative effect and AUC value, and between bone marrow suppression and Vc value. KEY WORDS Cisplatin; NSCLC; Pharmacokinetics; Pharmacodynamics; HPLC

关 键 词：顺铂 非小细胞肺癌 药动学 药效学 高效液相色谱法 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]